{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:13:53Z","timestamp":1780989233337,"version":"3.54.1"},"reference-count":54,"publisher":"The Journal of Health Economics and Outcomes Research","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHEOR"],"abstract":"<jats:p>Background\/Objectives: Among sickle cell disease (SCD) patients, vaso-occlusive crises (VOCs) are recurrent and unpredictable attacks of acute pain. These pain crises are often treated with analgesics, including opioids, which have been associated with misuse and overdose. The aim of this study was to examine the association between VOC events and opioid use and assess the association between opioid prescriptions and health care resource utilization among SCD patients.  Methods: This was a retrospective cohort study using Texas Medicaid medical and prescription claims between September 2011 and August 2016. The index date was the first SCD diagnosis. Patients (2\u201363 years) with at least one inpatient or two outpatient SCD diagnoses, who were continuously enrolled during 12 months postindex, were included in the study. The primary outcome was number of opioid prescriptions, while the independent variable was number of VOC events. Covariates included age, gender, nonopioid medication use, nonstudy SCD-related medication (penicillin and folic acid) use, evidence of blood transfusions, number of SCD-related complications, number of SCD-related comorbid conditions, and Charlson Comorbidity Index score. Negative binomial regression analysis was used to address study objectives.  Results: Of 3368 included patients, 1978 (58.7%) had at least one opioid prescription with a mean of 4.2 (SD=7.2). Overall, 2071 (61.5%) had at least one VOC event with an average of 2.9 (SD=4.4). The results from the negative binomial regression showed that for every increase in VOC events, the number of opioid prescriptions increased by 9.5% (Incidence rate ratio=1.095, 95% CI: 1.078\u20131.111; P \u2264 0.0001). Other significant covariates associated with higher opioid use included age (13 and older compared to 2\u201312) and increase in the number of nonopioid pain medications, nonstudy SCD-related medications, and SCD-related complications.  Conclusions: The majority of SCD patients had at least one VOC event and were prescribed opioids during the 12-month study period. We found that each VOC event was associated with a 9.5% increase in the use of opioids. SCD guidelines recommend opioids for the treatment of VOC-related pain. Payers and providers should be aware of opioid use in this population, consider appropriate VOC prevention measures, and provide SCD patients with access to appropriate pain management.<\/jats:p>","DOI":"10.36469\/jheor.2020.13348","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T22:10:03Z","timestamp":1593209403000},"page":"94-101","source":"Crossref","is-referenced-by-count":10,"title":["Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study"],"prefix":"10.36469","author":[{"given":"Hyeun Ah","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Barner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menaka","family":"Bhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincy","family":"Paulose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Kutlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","unstructured":"Centers for Disease Control and Prevention. What is sickle cell disease? Accessed March 10, 2020. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/facts.html"},{"key":"ref1","unstructured":"National Organization for Rare Disorders. Sickle cell disease. Accessed March 10, 2020. https:\/\/rarediseases.org\/rare-diseases\/sickle-cell-disease\/"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ajh.21807","article-title":"The burden of emergency department use for sickle-cell disease: An analysis of the national emergency department sample database","volume":"85","author":"Lanzkron","year":"2010","unstructured":"Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: An analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797-799.","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Amendah DD, Mvundura M, Kavanagh PL, Sprinz PG, Grosse SD. Sickle Cell Disease-Related Pediatric Medical Expenditures in the U.S. American Journal of Preventive Medicine. 2010;38(4):S550-S556. doi:10.1016\/j.amepre.2010.01.004","DOI":"10.1016\/j.amepre.2010.01.004"},{"key":"ref4","unstructured":"World Health Organization. Fifty-Ninth World Health Assembly, Geneva, 22-27 May 2006: Resolutions and Decisions: Annexes.; 2006. Accessed March 10, 2020. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA59-REC1\/e\/WHA59_2006_REC1-en.pdf"},{"key":"ref5","unstructured":"Hagemann TM, Lewis TV. Sickle cell anemia. In: Pharmacotherapy Principles & Practice. 3rd ed. McGraw-Hill Medical; 2013:1191-1206."},{"key":"ref6","unstructured":"Chan CYJ, Moore R. Sickle cell disease. In: Pharmacotherapy: A Pathophysiologic Approach. 7th ed. McGraw-Hill Medical; 2008:1685-1700."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yusuf HR, Lloyd-Puryear MA, Grant AM, Parker CS, Creary MS, Atrash HK. Sickle cell disease: The need for a public health agenda. American Journal of Preventive Medicine. 2011;41(6):S376-S383. doi:10.1016\/j.amepre.2011.09.007","DOI":"10.1016\/j.amepre.2011.09.007"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/19371918.2014.938396","article-title":"Challenges and resilience in the lives of adults with sickle cell disease","volume":"30","author":"Williams-Gray B","year":"2015","unstructured":"Williams-Gray B, Senreich E. Challenges and resilience in the lives of adults with sickle cell disease. Soc Work Public Health. 2015;30(1):88-105.","journal-title":"Soc Work Public Health"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic significance","volume":"79","author":"SK","year":"2005","unstructured":"Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17-25.","journal-title":"Am J Hematol"},{"issue":"18","key":"ref10","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: A critical reappraisal","volume":"120","author":"Ballas","year":"2012","unstructured":"Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood. 2012;120(18):3647-3656.","journal-title":"Blood"},{"issue":"24","key":"ref11","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: Pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","unstructured":"Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: Pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892-3898.","journal-title":"Blood"},{"issue":"6","key":"ref12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2165\/00019053-200220060-00001","article-title":"Sickle cell anaemia: Epidemiology and cost of illness","volume":"20","author":"Nietert","year":"2002","unstructured":"Nietert PJ, Silverstein MD, Abboud MR. Sickle cell anaemia: Epidemiology and cost of illness. Pharmacoeconomics. 2002;20(6):357-366.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"ref13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jpainsymman.2004.07.006","article-title":"Are there phases to the vaso-occlusive painful episode in sickle cell disease","volume":"29","author":"Jacob","year":"2005","unstructured":"Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease? J Pain Symptom Manage. 2005;29(4):392-400.","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","unstructured":"Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/s0027-9684(15)30725-2","article-title":"The impact of hydroxyurea on career and employment of patients with sickle cell anemia","volume":"102","author":"Ballas","year":"2010","unstructured":"Ballas SK, Bauserman RL, McCarthy WF, Waclawiw MA. Multicenter Study of Hydroxyurea in Sickle Cell Anemia. The impact of hydroxyurea on career and employment of patients with sickle cell anemia. J Natl Med Assoc. 2010;102(11):993-999.","journal-title":"J Natl Med Assoc"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15360288.2019.1577938","article-title":"Comparison of parenteral opioid dosing in adult sickle cell disease patients with vaso-occlusive crisis","volume":"32","author":"Shah","year":"2018","unstructured":"Shah SP, Twilla JD, Kemp L, Phelps GL, Reaves A. Comparison of parenteral opioid dosing in adult sickle cell disease patients with vaso-occlusive crisis. J Pain Palliat Care Pharmacother. 2018;32(4):201-207.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/asheducation-2007.1.97","article-title":"Current issues in sickle cell pain and its management","volume":"2007","author":"Ballas","year":"2007","unstructured":"Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program. 2007;2007(1):97-105.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"20","key":"ref18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Niihara Y, Koh HA, Tran L, et al. A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle \u00df0-Thalassemia. Blood. 2014;124(21):86-86. doi:10.1182\/blood.v124.21.86.86","DOI":"10.1182\/blood.V124.21.86.86"},{"issue":"6","key":"ref20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1067\/mpd.2001.119593","article-title":"Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia","volume":"139","author":"Miller","year":"2001","unstructured":"Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785-789.","journal-title":"J Pediatr"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Blinder MA, Barnes M, French K, Rogers C, Berger W. Outpatient opioid use in adult patients with sickle cell disease. Blood. 2013;122(21):4699-4699. doi:10.1182\/blood.v122.21.4699.4699","DOI":"10.1182\/blood.V122.21.4699.4699"},{"key":"ref22","unstructured":"Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I\/II trial. Blood. 1999;94(5):1550-1554."},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1067\/mpd.2001.119590","article-title":"A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia","volume":"139","author":"Wang","year":"2001","unstructured":"Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790-796.","journal-title":"J Pediatr"},{"issue":"13","key":"ref24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.","journal-title":"JAMA"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.20142","article-title":"Follow\u2010up of sickle cell disease patients with priapism treated by hydroxyurea","volume":"77","author":"Saad","year":"2004","unstructured":"Saad ST, Lajolo C, Gilli S, et al. Follow\u2010up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45-49.","journal-title":"Am J Hematol"},{"issue":"7","key":"ref26","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","unstructured":"Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood. 2005;106(7):2269-2275.","journal-title":"Blood"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease","volume":"86","author":"Candrilli","year":"2011","unstructured":"Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273-277.","journal-title":"Am J Hematol"},{"issue":"2","key":"ref28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/pbc.24178","article-title":"Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children","volume":"59","author":"JJ","year":"2012","unstructured":"Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012;59(2):365-371.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"ref29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1542\/peds.2014-0177","article-title":"Medication adherence among pediatric patients with sickle cell disease: A systematic review","volume":"134","author":"Walsh","year":"2014","unstructured":"Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: A systematic review. Pediatrics. 2014;134(6):1175-1183.","journal-title":"Pediatrics"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033. doi:10.1001\/jama.2014.10517","DOI":"10.1001\/jama.2014.10517"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Ballas SK. Update on pain management in sickle cell disease. Hemoglobin. 2011;35(5-6):520-529.","DOI":"10.3109\/03630269.2011.610478"},{"key":"ref32","unstructured":"National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. National Institutes of Health Accessed March 10, 2020. https:\/\/www.nhlbi.nih.gov\/health-topics\/evidence-based-management-sickle-cell-disease"},{"key":"ref33","unstructured":"National Institute for Health and Care Excellence. Sickle Cell Disease: Managing Acute Painful Episodes in Hospital. Clinical Guideline [CG143].; 2012. https:\/\/www.nice.org.uk\/guidance\/cg143"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624. doi:10.1001\/jama.2016.1464","DOI":"10.1001\/jama.2016.1464"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: A qualitative study. JAMA Netw Open. 2019;2(5):e194410. doi:10.1001\/jamanetworkopen.2019.4410","DOI":"10.1001\/jamanetworkopen.2019.4410"},{"key":"ref36","unstructured":"American Society of Clinical Oncology. CDC issues key clarification on guideline for prescribing opioids for chronic pain. April. https:\/\/www.asco.org\/about-asco\/press-center\/news-releases\/cdc-issues-key-clarification-guideline-prescribing-opioids. Published April 9, 2019."},{"key":"ref37","unstructured":"Centers for Medicare & Medicaid Services. The Invisible Crisis: Understanding Pain Management in Medicare Beneficiaries with Sickle Cell Disease. Vol 12.; 2018. Accessed March 10, 2020. https:\/\/www.cms.gov\/About-CMS\/Agency-Information\/OMH\/research-and-data\/information-products\/data-highlights\/Understanding-Pain-Management-in-Medicare-Beneficiaries-with-Sickle-Cell-Disease-.html"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"ref39","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.","journal-title":"Med Care"},{"issue":"6","key":"ref40","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"ref41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.36469\/9667","article-title":"Evaluation of vaso-occlusive crises in United States sickle cell disease patients: A retrospective claims-based study","volume":"6","author":"Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: A retrospective claims-based study. JHEOR. 2019;6(3):106-117.","journal-title":"JHEOR"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pds.4291","article-title":"Characterization of opioid use in sickle cell disease","volume":"27","author":"Han","year":"2018","unstructured":"Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018;27(5):479-486.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref43","unstructured":"Ballas SK, Kanter J, Agodoa I, et al. Opioid utilization patterns in United States patients with sickle cell disease. Blood. 2017;130(Supplement 1):130."},{"issue":"11","key":"ref44","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/ajh.24498","article-title":"Patterns of opioid use in sickle cell disease","volume":"91","author":"Han","year":"2016","unstructured":"Han J, Saraf SL, Zhang X, et al. Patterns of opioid use in sickle cell disease. Am J Hematol. 2016;91(11):1102-1106.","journal-title":"Am J Hematol"},{"key":"ref45","unstructured":"Yang W, Lawson K. A retrospective analysis of prescription opioid claims and expenditures by metropolitan statistical area status and county using Texas Medicaid pharmacy claims data. JMCP. 2020;26(4-a):S88."},{"issue":"9","key":"ref46","doi-asserted-by":"publisher","first-page":"886","DOI":"10.18553\/jmcp.2018.24.9.886","article-title":"Opioid analgesics in Georgia Medicaid: Trends in potential inappropriate prescribing practices by demographic characteristics, 2009-2014","volume":"24","author":"Jayawardhana","year":"2018","unstructured":"Jayawardhana J, Abraham AJ, Perri M. Opioid analgesics in Georgia Medicaid: Trends in potential inappropriate prescribing practices by demographic characteristics, 2009-2014. J Manag Care Spec Pharm. 2018;24(9):886-894.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"ref47","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1046\/j.1365-2141.2003.04193.x","article-title":"Guidelines for the management of the acute painful crisis in sickle cell disease","volume":"120","author":"Rees","year":"2003","unstructured":"Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120(5):744-752.","journal-title":"Br J Haematol"},{"key":"ref48","unstructured":"ADAKVEO (crizanlizumab). Package Insert. Novaritis Pharmaceuticals; 2019."},{"key":"ref49","unstructured":"OXBRYTA (voxelotor. Package Insert. Global Blood Therapeutics; 2019."},{"issue":"6","key":"ref50","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","unstructured":"Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.","journal-title":"Blood"},{"issue":"9","key":"ref51","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/pds.4860","article-title":"National trends in hydroxyurea and opioid prescribing for sickle cell disease by office\u2010based physicians in the United States, 1997-2017","volume":"28","author":"ZT","year":"2019","unstructured":"Su ZT, Segal JB, Lanzkron S, et al. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office\u2010based physicians in the United States, 1997-2017. Pharmacoepidemiol Drug Saf. 2019;28(9):1246-1250.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"ref52","doi-asserted-by":"publisher","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","unstructured":"Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.","journal-title":"Ann Intern Med"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Lanzkron S, Haywood C, Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008;100(8):968-973.","DOI":"10.1016\/S0027-9684(15)31420-6"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"link":[{"URL":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/pmid\/32685602\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:37Z","timestamp":1748875237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/13348-association-between-vaso-occlusive-crises-and-opioid-prescriptions-among-patients-with-sickle-cell-disease-a-retrospective-claims-based-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":54,"URL":"https:\/\/doi.org\/10.36469\/jheor.2020.13348","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}